je.st
news
Tag: merck
Merck Says Jury Rules in Its Favor in Fosamax Fracture Trial
2013-04-30 07:52:20| Biotech - Topix.net
Merck & Co., the second-biggest U.S. drugmaker, said a jury found in its favor in a trial over claims its Fosamax osteoporosis treatment caused a woman's femur to fracture spontaneously while she was gardening.
Merck, Pfizer partner on investigational diabetes drug
2013-04-29 23:28:36| Biotech - Topix.net
Merck & Co. Inc. and Pfizer Inc. have agreed to collaborate on the development of a combination drug for type 2 diabetes.
Tags: partner
drug
diabetes
merck
Merck Wins FOSAMAX (alendronate sodium) Federal Bellwether Trial Involving Atypical Femur Fracture Claims
2013-04-29 23:00:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, today said a jury found in its favor in the Glynn v. Merck case in the U.S. District Court for the District of New Jersey. In the case, the plaintiff claimed she used FOSAMAX and subsequently suffered an atypical femur fracture. Language: English Contact HTML: MerckMedia Contact:Lainie Keller, 908-423-4187orInvestor Contacts:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: trial
claims
federal
involving
Merck & Co., Inc. and Pfizer Enter Worldwide Collaboration Agreement to Develop and Commercialize Ertugliflozin, an Investigational Medicine for Type 2 Diabetes
2013-04-29 13:30:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. & NEW YORK WHITEHOUSE STATION, N.J. & NEW YORK--(BUSINESS WIRE)--Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada (Merck), and Pfizer Inc. (NYSE:PFE) today announced that they have entered into a worldwide (except Japan) collaboration agreement for the development and commercialization of Pfizers ertugliflozin (PF-04971729), an investigational oral sodium glucose cotransporter (SGLT2) inhibitor being evaluated for the treatment of type 2 diabetes. Language: English Contact HTML: Merck Media Relations:Steven Cragle: (908) 423-3461Kim Hamilton: (908) 423-6831orPfizer Media Relations:Joan Campion: (212) 733-2798orMerck Investor Relations:Carol Ferguson: (908) 423-4465Justin Holko: (908) 423-5088orPfizer Investor Relations:Chuck Triano: (212) 733-3901 Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: PFE Exchange: NYSE read more
Tags: for
type
enter
agreement
Merck Announces Breakthrough Therapy Designation for Lambrolizumab an Investigational Antibody Therapy for Advanced Melanoma
2013-04-24 13:30:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has designated lambrolizumab (MK-3475) as a Breakthrough Therapy for the treatment of patients with advanced melanoma. Lambrolizumab is Mercks investigational antibody therapy targeting Programmed Death receptor (PD-1) that is currently being evaluated for the treatment of patients with advanced melanoma, and other tumor types. Language: English Contact HTML: MerckMedia:Caroline Lapppetito, 267-305-7639orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: advanced
therapy
announces
designation
Sites : [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] [133] [134] [135] [136] [137] next »